Jean-Noel Freund
  • E-mail :[email]
  • Phone : +33 3 88 27 77 27 (std)
  • Location : INSERM UMR_S1113; Strasbourg, France
Last update 2016-11-26 02:57:25.565

Jean-Noel Freund PhD, Molecular Biology

Course and current status

Director of the Unit UMR_S1113 of INSERM / University of Strasbourg: Developmental and Cell Stress Signaling in Digestive and Urological Cancer

Leader of Team 1:  Intestinal Identity: from Stem Cells to Pathology

                                            - - - - - - - - - - - -

PhD in Cellular and Molecular Biology, University Louis Pasteur, Strasbourg, France (1986); LGME Inserm U184, dir: Prof P Chambon:  The rudimentary gene of Drosophila melanogaster: structure, expression and function 
  

Scientific summary

The UMR_S1113 is composed of 3 teams.

> Team 1 (Leader JN Freund): Intestinal identity: from stem cells to pathology.

> Team 2 (Leader C Gaiddon): Molecular mechanism of the stress response and pathologies.

> Team 3 (Leader T Massfelder): Cell signaling and communicaiton in kidney and prostate cancer.

                                                       --------------------

Team 1. Our work explores the mechanisms of tissue identity in gastrointestinal stem cells during development and homeostasis, and their perturbations in cancer and inflammatory diseases. It is based on our recent data showing (i) the relevance of the Cdx2 and Numb genes in the identity and function of intestinal stem cells and their progeny, and (ii) the complexity of the Cdx2 network that is regulated at multiple levels and that controls novel functions through original transcription targets (ie the Mucdhl/Cdhr5 gene) and protein partners (ie the KU70/80 complex).

The project aims at understanding: (1) how the intestinal identity is translated at the level of stem cells to impose a mode of symmetric / asymmetric division compatible with the morphology, polarity and differentiation of the gut epithelium; (2) what are the consequences of the alteration of these processes in colorectal cancers, inflammatory bowel diseases and premalignant and malignant intestinal-type pathologies outside the gut; (3) how these alterations impact on the efficacy of the response to therapeutic treatments.

Image d’exemple